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Abstract
The recent genome-wide analysis of carotid–femoral pulse wave velocity (PWV) identified a significant locus within the
14q32.2 gene desert. Gene regulatory elements for the transcriptional regulator B-cell CLL/lymphoma 11B (BCL11B) are
within this locus and an attractive target for the gene association. We investigated the functional impact of these gene desert
SNPs on BCL11B transcript in human aorta to characterize further its role in aortic stiffness. To do this, we used a large
repository of aortic tissues (n= 185) from an organ transplant program and assessed ex vivo stiffness of the aortic rings. We
tested association of three lead SNPs from the GWAS meta-analysis with ex vivo aortic stiffness and BCL11B aortic mRNA
expression: rs1381289 and rs10782490 SNPs associated significantly with PWV and showed allele-specific differences in
BCL11B mRNA. The risk alleles associated with lower BCL11B expression, suggesting a protective role for BCL11B.
Despite strong association, we could not detect BCL11B protein in the human aorta. However, qPCR for CD markers
showed that BCL11B transcript correlated strongly with markers for activated lymphocytes. Our data confirm the
significance of the 14q32.2 region as a risk locus for aortic stiffness and an upstream regulator of BCL11B. The BCL11B
transcript detected in the human aorta may reflect lymphocyte infiltration, suggesting that immune mechanisms contribute to
the observed association of BCL11B with aortic stiffness.
Introduction
Aortic stiffness (AS) underlies systolic hypertension, pro-
motes heart failure and is associated with increased
cardiovascular (CV) morbidity and mortality [1]. AS
strongly correlates with left ventricular hypertrophy and
aortic aneurysms [2, 3] and is linked to the pathogenesis of
cognitive impairment, stroke and renal failure [3].
Carotid–femoral pulse wave velocity (cfPWV), the current
gold-standard measure of AS, is an independent predictor of
CV events and all-cause mortality in both healthy indivi-
duals and high-risk groups, including end-stage kidney
disease, hypertension, and diabetes [4].
As with most other CV traits, AS is genetically complex
and moderately heritable, but precise molecular mechan-
isms are still lacking. The most recent genome-wide ana-
lysis of cfPWV in the AortaGen Consortium identified a
significant locus on chromosome 14 [5]. The top signals
from this genome-wide association study (GWAS) meta-
analysis reside in a gene-poor region (14q32.2), although
the region contains regulatory elements that may influence
AS by regulating gene expression in a trans and tissue-
specific manner. In fact, the cfPWV locus maps to an
enhancer for B-cell chronic lymphocytic leukemia/lym-
phoma 11B (BCL11B), which resides ~ 850 kb upstream
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from the locus [6]. BCL11B, also known as chicken oval-
bumin upstream promoter transcription factor (COUP-TF)
interacting protein 2 (CTIP2), is a typical transcriptional
regulator with six C2H2-like zinc finger domains. It is an
attractive AS candidate for several reasons. It is highly
expressed and crucial to cutaneous, immune, and central
nervous system function and is a key regulator of adipo-
genesis [7–9]. BCL11B also governs crucial aspects of the
development, differentiation, recruitment, and function of T
lymphocytes and other immune cells [10]. Significantly, for
blood vessels, the interaction of BCL11B with the COUP-
TFII nuclear receptor regulates arterial–venous blood vessel
identity [11, 12]. Additionally, altering the expression of
BCL11B perturbs several genes and signaling pathways that
have recognized roles in vascular calcification and extra-
cellular matrix synthesis, deposition, turnover, and assem-
bly [9, 13, 14]. Clinical support also comes from the recent
Twins UK Cohort, where BCL11B transcript levels in cir-
culating lymphocytes were correlated with cfPWV and
decreased carotid distensibility [15].
Despite the accumulating evidence implicating BCL11B
as a novel candidate gene for AS, its exact molecular
role remains unclear. Our working hypothesis has been that
it may regulate the expression of genes that either directly
regulate the architecture of the vessel wall or promote
vascular calcification and/or inflammation. Hence, we
undertook this study to examine the functional impact
of the lead single-nucleotide polymorphisms (SNPs) from
the AortaGen Consortium on aortic BCL11B transcript
levels and on ex vivo measurements of AS in a large
sample of human aortic tissues as well as to determine




Aortic tissue samples were harvested from organ donors
through transplant coordinators at Addenbrooke’s Hospital,
Cambridge. Fresh tissue from the ascending, arch, thoracic,
and abdominal segments of the aorta and iliac arteries were
preserved in tissue medium at the time of organ donation.
Tissues were cleaned of adherent blood vessels or adipose
tissues and then stored at −80 °C. Two-cm rings were cut
for biophysical measurements and sections were preserved
in RNAlater® for RNA extraction.
Demographic data, anthropometric information, bio-
chemical and hemodynamic measurements, medical and
drug history (past and at the time of death) where available,
cause of death, and other details that may have affected AS
were recorded. All samples and donor data were handled in
accordance with the policies and procedures of the Human
Tissue Act (UK). The Local and Regional Ethics Com-
mittees approved the study (MREC/03/2/074).
Biophysical measurements
Aortic ring diameter and wall thickness were recorded with
digital calipers, and Young’s modulus (EM) was measured
using an Instron 5542 tensile test machine controlled by the
Bluehill 2 software as detailed elsewhere [16]. Briefly, each
ring was cycled 5 times in the range of 0–200 mmHg at a
rate of 10 mm/min. EM at a load of 100 mmHg was used to





where h is wall
thickness, r is the arterial radius, and ρ is blood density
(taken as 1.05 g/cm3) [16].
DNA extraction and SNP genotyping
Genomic DNA was extracted from thawed aortic tissue
following the manufacturer’s guidelines of the QIAmp
DNA Mini Kit (QIAGEN). DNA quantity and purity were
checked on a NanoDrop spectrophotometer ND100. The
three SNPs used (IDs from build 151 of dbSNP) were:
rs1381289 (ch14:g.98126027C>T), rs10782490 (ch14:
g.98083046C>T), and rs17773233 (ch14:g.98116322G>T)
and genotyped using TaqMan SNP Genotyping assays
(ThermoFisher Scientific). They were the top SNPs in the
previous AortoGen meta-analysis and are in tight linkage
disequilibrium (D’= 1; rs1381289 vs rs10782490 R2=
0.78, rs1381289 vs rs17773233 R2= 0.42, rs10782490 vs
rs17773233 R2= 0.32). Allelic discrimination was carried
out using the ABI 7500 Detection System (ThermoFisher
Scientific). The genotyping data for the three SNPs together
with the corresponding phenotypic data from our donor
cohort has been deposited publically on the Leiden Open
Variant Database (http://www.lovd.nl/3.0/home) at https://
databases.lovd.nl/shared/variants/0000368472. The sum-
marized phenotypic data by genotype is also included as a
table in Supplementary File.
RNA extraction and cDNA preparation
Total RNA was extracted from aortic tissue preserved in
RNAlater® Stabilization Solution (ThermoFisher Scientific)
using the RNeasy Fibrous Tissue Mini Kit (QIAGEN) fol-
lowing the manufacturer’s guidelines. Peripheral blood
mononuclear cell (PBMC) total RNA was extracted using
the PaxgeneTM Blood RNA Validation Kit (PreAnalytix).
RNA quantity and purity were determined using the
NanoDrop ND100 spectrophotometer. Complementary
DNA (cDNA) was generated using the GoScriptTM
Functional characterization of common BCL11B gene desert variants suggests a lymphocyte-mediated. . . 1649
Reverse Transcription System (Promega), and cDNA sam-
ples were stored at −20 °C until analyzed.
Gene expression
Gene expression levels of BCL11B, CD45, CD25, CD8α,
and CD235α were quantified using TaqMan® probe and
primers (assay IDs: BCL11B Hs01102259_m1 human;
CD45 PTPRC Hs 04189704_m1; CD25 IL2RA Hs
00907778_m1; CD8α Hs00233520_m1; CD235α
Hs01068072_m1, ThermoFisher Scientific). Human
GAPDH endogenous control (assay ID: 4326317E, Ther-
moFisher Scientific) was used to normalize the data. Real-
time PCR was performed in duplicate using the TaqMan®
Fast Advanced Master Mix (ThermoFisher Scientific) using
1.5 μl stock cDNA template. Gene expression data are
represented as 2−ΔCt where ΔCt=GAPDH Ct−target gene
Ct [17].
Western blotting
Frozen aortic tissues were homogenised using TissueLyser
LT (QIAGEN) and protein lysates were extracted in
NE-PER nuclear and cytoplasmic extraction buffers (Ther-
moFisher Scientific) containing protease inhibitors (Cal-
biochem). Full-length CTIP2 expressed in a pcDNA3.1
vector and transfected into HEK293T cells was used as a
positive control for the antibody and empty vector trans-
fected into HEK293T cells was used as a negative control.
Cells were lysed using RIPA buffer and protein con-
centrations were determined with the PierceTM BCA pro-
tein assay (ThermoFisher Scientific). Protein lysates (10 μg)
were incubated in a Laurel DuodecylSulfate sample loading
buffer and Bolt® sample reducing agent (ThermoFisher
Scientific) before loading and separation by sodium dodecyl
sulfate-gel electrophoresis in 4–12% gradient Bis-Tris Plus
Bolt® gels (ThermoFisher Scientific) at 200 V for 30 min.
They were transferred to 0.22 μM nitrocellulose membrane
(ThermoFisher Scientific) using the iBlot2 dry blotting
system (ThermoFisher Scientific) and blocked with 5% (wt/
vol) milk in TBS buffer and then incubated with primary
antibodies in TBS-Tween (0.1% Tween 20) for 16 h at 4 °C.
Secondary antibodies were incubated in TBS-Tween for 1 h
at room temperature (RT) in the dark. Membranes were
washed in TBS-Tween 3× for 15 min between primary and
secondary antibody incubations and visualized using the LI-
COR Odyssey system.
Immunohistochemical (IHC) staining
IHC staining was performed in formalin-fixed, paraffin-
embedded (FFPE) aortic samples. Human tonsil sections
were used as a positive control. Briefly, 4 µm sections were
deparaffinized in Histoclear (National Diagnostics) and then
dehydrated through graduated alcohols. Antigen retrieval
was performed in R-Universal epitope recovery buffer
(Aptum Biologics Ltd #AP0530-125) using 2100 Retriever
(Aptum Biologics Ltd). EnVisionTM+Dual Link system
(Dako) was used for chromogenic detection of the primary
antibodies. Sections were counterstained with hematoxylin
(Sigma-Aldrich), rehydrated through graduated alcohols,
cleared in Histoclear, and then mounted with Histomount
(National Diagnostics).
Immunofluorescence staining with tyramide signal
amplification (TSA)
TSA staining was performed on three FFPE aortic sections
that showed highest BCL11B mRNA and tonsil sections
were used as a positive control. As TSA is catalyzed by
peroxidase, endogenous peroxidase activity was quenched
with 3% H2O2 in methanol for 30 min. Sections were
blocked in TNB buffer made with 0.1 M Tris-HCl (pH 7.5),
0.15 M NaCl and 0.5% Blocking Reagent (FP1012,
PerkinElmer) for 1 h at RT followed by primary antibody
incubation in TNB buffer for 1 h at RT. Sections were
washed in TNT wash buffer (0.1 M Tris-HCl, 0.15 M NaCl,
and 0.05% Tween-20) and then incubated in horseradish
peroxidase-conjugated secondary antibody (Sigma-Aldrich)
diluted at 1:1000. Sections were incubated in 200 μl TSA
Plus Fluorescein working solution (PerkinElmer) for 5 min
and washed in TNT buffer. Sections were counterstained
with Sytox® Orange (ThermoFisher Scientific), mounted
with ProLong® Gold, and cured overnight before visuali-
zation with Leica SP8 confocal laser scanning microscope.
Antibodies
BCL11B/CTIP2 expression in the aorta was probed using
five antibodies that recognize different epitopes on CTIP2:
anti-CTIP2 rat monoclonal (Abcam, ab18465), rabbit
polyclonal (Abcam, ab70452), rabbit polyclonal (Abcam,
ab28448), rabbit monoclonal (Abcam, ab187668), and
rabbit monoclonal (CST signaling 12120). Western blot and
IHC staining antibody dilutions were used as recommended
by the manufacturer. CD45 expression in the aorta was
probed with anti-CD45 rabbit polyclonal (Abcam, ab10558)
at 1:2000 dilution. Beta-actin rabbit polyclonal immu-
noglobulin G (ThermoFisher Scientific) was used for the
western blot loading control at 1:1000 dilution. Donkey
anti-rabbit (LI-COR) IRDye® 800CW and goat anti-rat
(ThermoFisher Scientific) Alexa Fluor® 680-conjugated
secondary antibodies were used at 1:5000 dilution for
western blot.
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BCL11B expression in mice
Brain, thymus, spleen and whole aortic tissues were har-
vested from 10-week-old wild-type mice (n= 9) and pre-
served in either RNAlater® for gene expression and western
blotting and then stored at −80 °C or in 4% (vol/vol) par-
aformaldehyde overnight for IHC staining. The aortae were
perfused with RNA-free phosphate-buffered saline three
times immediately after harvesting to remove blood and
adipose tissue was trimmed from aortic samples before
western blotting and gene expression. RNA was extracted
using the RNeasy Mini Kit (QIAGEN) and cDNA was
generated using GoScriptTM Reverse Transcription (Pro-
mega) as described above. BCL11B mRNA was probed
using TaqMan® gene expression assay (Mm00480516_m1)
and Eukaryotic 18S rRNA Endogenous Control (Thermo-
Fisher Scientific) for normalization. Protein was extracted
from tissues using RIPA buffer supplemented with protease
inhibitors (Calbiochem). BCL11B was probed using rabbit
polyclonal anti-BCL11B (Abcam, ab70452) at 1:200 dilu-
tion for western blotting as described earlier. The EnVi-
sionTM+Dual Link system (Dako) was used for IHC
detection with rabbit polyclonal anti-BCL11B (Abcam,
ab70452) at 1:1000 dilution.
BCL11B was further probed in tissues harvested from
10-week-old BCL11B-tdTomato reporter mice [16]. The
reporter mice were a C57BL/6 background and the tdTo-
mato cassette (loxP-IRES-dtTomato) was targeted to the 3’
untranslated region of BCL11B. To generate conditional
knockouts, mice were injected with tamoxifen 1 week prior
to tissue harvesting resulting in deletion of exon 4 of
BCL11B. Rabbit polyclonal anti-RFP (Rockland Immuno-
chemicals, 600–401–379) was used at 1:2000 dilution for
western blot detection. Human colorectal cells expressing
tdTomato (generous gift from Fatima Junaid, Cancer
Research UK, Cambridge) were used as positive control.
Statistical analysis
Statistical analyses were conducted using the SPSS version
23 and GraphPad Prism 7 software. As the thoracic section of
the aorta differs histologically and embryologically from the
abdominal segment, statistical analysis used samples from
the ascending aorta, arch and thoracic aorta only (n= 185
of the 209 aortae collected). Deviations from the
Hardy–Weinberg equilibrium were tested using χ2 test. For
each SNP, t tests were used to compare BCL11B mRNA
differences between the two homozygous allele carriers. Since
SNP genotype showed a dose-dependent pattern of inheri-
tance on the phenotype (PWV and BCL11B mRNA), SNP
associations with PWV were tested assuming a standard
additive model using regression models adjusted for factors
that influence PWV (age, age2, gender, height, and weight).
Spearman’s correlation coefficients were used to determine
correlations between BCL11B and CD markers. In all sta-
tistical tests, a P value <0.05 was considered significant.
Results
The clinical and demographic features of the donor samples
are provided in Table 1. Less than 10% had established CV
disease or were diabetic. However, a third of the aortic
donors were hypertensive.
Association of 3’BCL11B gene desert SNPs with AS
We investigated the association of AS measured ex vivo in
donor aortae with the lead SNPs from the AortaGen Con-
sortium GWAS meta-analysis. Hardy–Weinberg equili-
brium was satisfied for all the SNPs tested (Table 2). Allele
frequencies of the SNPs in our aortic tissue resource were
comparable to those observed in the GWAS meta-analysis.
The minor allele frequencies were 0.45 vs 0.44 for
rs1381289, 0.50 vs 0.47 for rs10782490, and 0.19 vs 0.19
for rs17773233 (donor aortae vs AortaGen Consortium).
All three SNPs from the GWAS meta-analysis (rs1381289,
rs10782490 and rs17773233) showed an allele–dose trend
with calculated PWV (PWVMK, Fig. 1). Multiple linear
regression models including traditional confounders for PWV
(age, age2, gender, height, and weight) showed that two SNPs
(rs1381289 and rs10782490) associated significantly and
independently with PWV (Table 3).




Male/female (n) 122/87 —
Age (years) 57 (19) 17–83
Height (m) 1.7 (0.2) 1.45–2.0
Weight (Kg) 80 (20) 47–160
BMI (Kg/m2) 27.04 (6) 16–69
SBP (mmHg) 120 (32) 40–260
DBP (mmHg) 68 (14) 20–120
Elastic modulus (MPa) 0.14 (0.09) 0.05–0.63
PWVMK (m/s) 3.53 (0.97) 2.4–9.49
CVD (n) 21 —
HT on treatment (n) 62 —
Diabetes (n) 16 —
Hyperlipidemia (n) 9 —
Data are median (IQR)
BMI body mass index, SBP systolic blood pressure, DBP diastolic
blood pressure, PWVMK pulse wave velocity calculated using
Moens–Kortweg equation, CVD cardiovascular disease, HT
hypertension
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3’BCL11B gene desert SNPs and aortic BCL11B gene
expression
Because the SNPs investigated lie within a region harboring
gene regulatory elements, we looked for evidence that these
variants had distal regulatory effects on BCL11B transcript,
the nearest known gene (upstream) of this locus on the minus
strand. We estimated allelic effects by comparing the mean
expression of BCL11B mRNA in the two homozygote classes
for each SNP (Fig. 1b). The homozygous CC of the lead
SNP rs1381289 showed three-fold higher mean BCL11B
expression compared with the homozygous T allele (P=
0.0005). Heterozygous individuals displayed an intermediate
phenotype. Consistent with this, the homozygous risk allele
(CC) of rs10782490 also showed lower BCL11B transcript
compared with the homozygous T allele (1.8-fold, P= 0.05).
However, BCL11B transcript levels were not significantly
influenced by rs17773233 genotype, although there was a
trend toward lower BCL11B mRNA among carriers of the
risk allele. Together, this data demonstrates that two of the
risk SNPs are associated with lower BCL11B expression and
behave as expression-SNPs (e-SNPs). We further examined
the expression pattern of BCL11B along the length of the
aorta and found that BCL11B transcript was most abundant in
Table 2 Chromosome 14
polymorphisms with genotype
and allele frequencies
SNPs Genotypes N (%) Hardy–Weinberg test Alleles N (%)
rs1381289 (C>T) CC 60 (29.1) χ2= 0.312 C 226 (54.9)
CT 106 (51.5) P= 0.576 T 186 (45.1)
TT 40 (19.4)
rs10782490 (C>T) CC 49 (23.9) χ2= 0.395 C 205 (50.0)
CT 107 (52.2) P= 0.530 T 205 (50.0)
TT 49 (23.9)
rs17773233 (G>T) GG 138 (66.4) χ2= 0.098 G 338 (81.2)
GT 62 (29.8) P= 0.754 T 78 (18.8)
TT 8 (3.8)
Fig. 1 Association of
3’BCL11B gene desert SNPs
with (a) calculated PWV and
(b) BCL11B mRNA in human
aortic tissues. Boxes are
interquartile ranges, the lines
within boxes are median values
and whiskers are 5th and 95th
percentiles. *P < 0.05 for
comparison of the two
homozygous genotypes
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the ascending aorta, followed by the thoracic, abdominal
aorta, and iliac arteries (Supplementary Fig. 1).
No evidence of BCL11B/CTIP2 protein expression in
the human aorta
To examine the functional significance of BCL11B in the
adult aorta, we probed its expression using antibodies that
target different epitopes on the protein. We selected samples
from the extreme ends of the PWV spectrum (low PWV and
high PWV, n= 15 in each group) as well as additional
(n= 15) samples that had the highest BCL11B gene
expression. We did not detect CTIP2 in any of these sam-
ples using either western blotting of aortic homogenates or
IHC staining of FFPE sections (Fig. 2a–c). We also used
TAS to increase the detection sensitivity of the IHC but still
failed to identify BCL11B in the human aorta (Supple-
mentary Fig. 2). This led us to question whether BCL11B is
constitutively expressed in aortic smooth muscle cells
(AoSMCs) or whether the levels detected in the aortic tissue
samples reflected underlying infiltration from circulating
lymphocytes. In fact, BCL11B gene expression quantified
using real-time quantitative PCR (qPCR) in cultured primary
human AoSMCs was negligible (2−ΔCt: 0.003 ± 0.0005,
n= 3) compared to that in PBMCs (724.4 ± 10.09, n= 3) or
HEK293T cells (5.5 ± 0.16, n= 3, Fig. 2a), which have been
reported in the literature to lack BCL11B expression.
No evidence of BCL11B protein expression in the
mouse aorta
The expression pattern of BCL11B was examined in wild-
type 10-week-old mice, with the thymus, spleen and brain
as positive controls (Supplementary Fig. 3A). Similar to the
patterns observed in human tissues, BCL11B gene expres-
sion was detected in the aorta but at very low levels (2−ΔCt:
0.0003 ± 0.00001, n= 3) compared to the thymus (0.31 ±
0.006, n= 3) and spleen (0.029 ± 0.002, n= 3). BCL11B
was below detection limits in western blots of aortic
homogenates and IHC staining of FFPE sections of wild-
type mice (Supplementary Fig. 3B-C). Similarly, BCL11B
was below detection limits in western blots of aortic
homogenates from BCL11B-tdTomato-expressing reporter
mice using an anti-RFP antibody (Supplementary Fig. 4).
BCL11B expression in the aorta reflects T cell
infiltration
Since lymphocytes express BCL11B at high levels, we
explored the possibility that aortic BCL11B gene expres-
sion reflected lymphocyte infiltration. We examined whe-
ther BCL11B transcript levels correlated with specific
lymphocyte markers in randomly selected aortic samples (n
= 85, Fig. 3a–c). We quantified the transcript levels of
leukocyte common antigen CD45, the cytotoxic T-
lymphocyte marker CD8α, and the activated T-
lymphocyte marker CD25. BCL11B transcript correlated
strongly with CD45 (r= 0.87, P < 0.0001), CD8α (r=
0.81, P < 0.0001), and CD25 (r= 0.80, P < 0.0001). This
interpretation was further supported by IHC staining for
CD45 in the aorta that showed higher levels of staining in
the aortas with high BCL11B mRNA expression (Supple-
mentary Fig. 5). We also considered whether these positive
associations were due to inadequate removal of residual
blood from the tissue samples by quantifying the expression
of the specific erythrocyte marker CD235α. However,
BCL11B gene expression did not correlate with CD235α
gene expression (r=−0.02, P > 0.05, Fig. 3d).
Discussion
Robust associations of genetic variants with cfPWV were
identified in the most recent GWAS meta-analysis of
>20,000 individuals. As with most complex traits, attaching








Dependent variable: inverse PWV
Age 1.967 5.993 <0.001
Age2 −2.495 −7.708 <0.001
Gender −0.009 −0.127 0.899
Height 0.063 0.773 0.441
Weight −0.049 −0.765 0.445
rs1381289 C>T −0.157 −2.746 0.007
Adjusted R2= 0.446; F= 24.074; P < 0.001
Age 1.877 5.627 <0.001
Age2 −2.409 −7.273 <0.001
Gender 0.003 0.043 0.966
Height 0.073 0.892 0.374




Adjusted R2= 0.432; F= 22.663; P < 0.001
Age 1.900 5.726 <0.001
Age2 −2.428 −7.408 <0.001
Gender 0.023 0.318 0.751
Height 0.079 0.971 0.333




Adjusted R2= 0.429; F= 22.766; P < 0.001
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biological function to these variants remains a challenge,
especially when the risk locus lies in a gene desert. A
growing body of evidence supports tissue-specific, long-
range regulatory mechanisms for GWAS-identified risk
SNPs [18–20]. The region of cfPWV association harbors
gene-enhancer elements, such as DNAse-I hypersensitive
sites, transcription factor-binding sites, and signatures of
chromatin modification [5], and the region is able to drive T
cell-specific BCL11B expression in a reporter system [6].
Hence, we examined whether the GWAS SNPs could drive
BCL11B transcription. Using our human aortic resource,
we found evidence that rs1381289 and rs10782490 are e-
SNPs as BCL11B mRNA levels were significantly influ-
enced by the genotype of these SNPs. Our data support
BCL11B as a potential causal gene and suggest an inverse
relationship between BCL11B transcript levels and PWV.
We provide further evidence of the biological importance
of the 14q32.2 locus by demonstrating associations for two
of the lead SNPs from the GWAS meta-analysis, rs1381289
and rs10782490, with PWV measured ex vivo in the
proximal aorta. It is important to distinguish the molecular
contributors of AS in the elastin-rich proximal aorta from
the embryologically distinct and collagen-rich distal aorta.
This is highlighted by regional differences in the BCL11B
expression along the arterial tree (Supplementary Fig. 1),
being higher in the ascending and thoracic aorta compared
to the distal abdominal aorta and iliac arteries. An under-
standing of how these genetic variations influence AS is key
for our better understanding of the molecular mechanisms
that modify cfPWV.
Despite strong evidence for its association with AS, we
found no evidence of BCL11B protein expression in our
adult human aortas. Likewise, we did not detect BCL11B
mRNA in cultured AoSMCs using the same qPCR assay. In
view of this puzzling finding, and given that BCL11B is
highly expressed in human T lymphocytes, we questioned
whether it is constitutively expressed in the aorta, perhaps
rapidly switched off in AoSMCs in culture, or whether what
we detected is simply transcript abundance from infiltrating
lymphocytes. In fact, BCL11B gene expression correlated
strongly with markers for total leukocytes and both acti-
vated and cytotoxic T lymphocytes, implying that immune
mechanisms may underlie the association of BCL11B with
AS. Lymphocytes have an important role in hypertension
Fig. 2 Aortic expression of BCL11B. (a) Bar chart showing reduction
in BCL11B mRNA expression in cultured human aortic vascular
smooth muscle cells is insignificant compared to PBMC and
HEK293T cells. (b) Representative western blot of aortic BCL11B
shows negative staining across nuclear and cytoplasmic homogenates
of (I) low PWV samples, (II) high PWV samples, and (III) samples
with the highest BCL11B mRNA levels. Positive control is protein
lysate of HEK293T-expressing full-length BCL11B and negative
control is protein lysate of HEK293T expressing an empty vector
control. (c) Representative immunohistochemical staining of (n= 45)
aortic samples shows lack of BCL11B expression in the aorta. Tonsil
was used as a positive control for the antibody (scale bar= 50 μM)
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and the pathophysiological changes that result in the vessel
wall [21]. Loss of BCL11B signaling can also have a
proinflammatory stimulus. For example, the colons of mice
lacking BCL11B display significant levels of infiltrated
proinflammatory T helper type 1 (Th1) and Th17 CD4+
T cells, neutrophils and macrophages and develop inflam-
matory bowel disease [22]. A similar, BCL11B-dependent
perturbation of the inflammatory system and inflammasome
has been reported in other cell types. For example,
inflammatory cell infiltration has been reported in the mouse
epidermis where selective silencing of BCL11B in kerati-
nocytes increased the infiltration of eosinophils, monocytes,
CD3+ and CD4+ T lymphocytes, and CD45+ leukocytes in
the skin [23]. Overall, the evidence indicates that BCL11B
regulates a number of elements in the inflammatory path-
way. And we would speculate that differential BCL11B
Fig. 3 Aortic BCL11B
expression correlates with
leukocyte markers. Plots of
BCL11B mRNA against and
CD8α (a), CD25 (b), and CD45
(c) transcript levels (n= 85)
showing a strong positive
correlation between BCL11B
and these leukocyte markers.
There is no correlation with the
erythrocyte marker CD235α (d).
For both SNPs, the genotypes
are shown as filled symbols (CC
black, CT black/white, and TT
white)
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expression among the SNP haplotypes modulates the lym-
phocyte infiltration signal we have identified.
An obvious question from our study is how a high
BCL11B transcript abundance can be protective (associat-
ing inversely with AS) if the expression of BCL11B is
proinflammatory. The aortas in our subjects clearly do not
show histological evidence of inflammation in the sense of
neutrophil or macrophage invasion. Recent work on lym-
phocyte subpopulations that are regulated by BCL11B are
relevant here. Studies on type-2 innate lymphoid cells
(ICL2) have shown them to have a key protective role in
atherosclerosis [24]. In fact, mice genetically depleted of
ICL2 lymphocytes show increased atherosclerosis [24]. The
behavior of mature ICL2 lymphocytes is also tightly con-
trolled by BCL11B including their eventual cytokine profile
[25]. This suggests that ICL2s may be protective in the
vessel wall, which clearly needs further exploration. It may
be that peripheral ICL2 burden is predictive of PWV. If this
were the case, it opens the way to possible therapeutic
modulation of ICL2 function with exogenous Il-2 [24]. It
also suggests a testable mouse model, as mice genetically
depleted of ICL2 lymphocytes may have stiffer aortas than
mice with replete ICL2 lymphocyte populations.
BCL11B may not be the only effector gene controlled
by the 14q32.2 locus. The GWAS signal may modulate
AS as part of a larger interplay of transcriptional regula-
tion involving other targets flanking the 14q32.2 gene
desert. Human vaccinia-related kinase 1 (VRK1) for
instance lies ~ 1.1 MB centromeric to the locus. This
prominent serine–threonine kinase in the nucleus com-
plexes and promotes the stabilization and accumulation of
p53 [26, 27]. Importantly, P53 is a transcription factor that
tightly regulated by the transforming growth factor-β
signaling cascade, itself a common pathway that underlies
inherited aortopathies such as Marfan and Loeys–Dietz
syndromes [28, 29]. Finally, p53 may itself be a target of
BCL11B transcriptional control [30], so independent
effects on VKR1 and BCL11B transcription potentially
converge and potentiate AS. Close to the locus is the
primate-specific, long non-coding RNA (lncRNA),
DB129663. The enhancer region maps to the DB129663
promoter, and it is hypothesized that it is a target of the
enhancer elements of the 14q32.2 gene desert [5].
LncRNAs are emerging as key players in transcriptional
regulation, posttranscriptional modification, and epige-
netic modulation and may therefore be central to the
association of this region with AS [31]. The functional
characteristics and expression patterns of DB129663,
however, are currently unknown.
In conclusion, this is the first study investigating the role
of the BCL11B gene desert SNPs on BCL11B expression
and PWV measured ex vivo in a large sample of human
aortas. We were unable to detect BCL11B at the protein
level but provide evidence that suggests that the BCL11B
transcript detected in the human aorta reflects lymphocyte
infiltration. So we hypothesize that it is immune mechan-
isms that largely govern the association of BCL11B with
AS. Further work incorporating other putative targets of the
14q32.2 enhancer elements may delineate the precise
molecular mechanisms by which this locus can affect the
stiffening process.
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